Market revenue in 2023 | USD 101.0 million |
Market revenue in 2030 | USD 160.7 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Attenuated vaccine |
Fastest growing segment | DNA Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 30.4% in 2023. Horizon Databook has segmented the Australia vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Australia has one of the best healthcare systems in the world. The increasing awareness about the need for early detection of lifestyle and chronic diseases is expected to boost the market in the country. Similar to governments of developed economies, the Australian government undertakes schemes to provide medicines at subsidized rates.
For instance, as per the Pharmaceutical Benefits Scheme (PBS), medicines are available for all eligible patients at a subsidized cost. These factors are expected to improve & promote the demand for pharmaceutical manufacturing, thus boosting the demand for vaccine contract manufacturing services in the country.
Adopting advanced manufacturing technologies and processes can enhance efficiency, reduce costs, & improve the overall quality of oral solid dosage manufacturing. This is expected to support the demand for vaccine manufacturing in Australia and create opportunities for CMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account